| Deramus Hearing Aid Centera | |
|
2809 Chestnut St, Montgomery, AL 36107-3007 | |
| (334) 262-7553 | |
| (334) 261-3132 |
| Full Name | Deramus Hearing Aid Centera |
|---|---|
| Type | Facility |
| Speciality | Hearing Instrument Specialist |
| Location | 2809 Chestnut St, Montgomery, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508100835 | NPI | - | NPPES |
| 1689954976 | Other | AL | NPI |
| 1124308366 | Other | FL | NPI |
| 1801040621 | Other | AL | NPI |
| 1962754010 | Other | FL | NPI |
| 1578892642 | Other | AL | NPI |
| Mailing Address | Practice Location Address |
|---|---|
| Deramus Hearing Aid Centera 2809 Chestnut St, Montgomery, AL 36107-3007 Ph: (334) 262-7553 | Deramus Hearing Aid Centera 2809 Chestnut St, Montgomery, AL 36107-3007 Ph: (334) 262-7553 |
News Archive
Fitch Ratings has assigned an 'AA' to Partners HealthCare System's approximately $475 million Massachusetts Health and Educational Facilities Authority revenue bonds (Partners HealthCare System), fixed-rate revenue bonds, series 2009J, which are expected to be sold as two sub series. Fitch also affirms its 'AA' long-term rating on all of Partners' outstanding debt and affirms its 'F1+' rating on approximately $485 million of Partners HealthCare System's debt that is backed by self-liquidity.
KIKA™ Clinical Solutions announced the successful completion of its ISO renewal audit for its operations in the U.S. and France. KIKA is the leading provider of advanced EDC solutions for Clinical Asset Management™ for the pharmaceutical, biotechnology and medical device markets.
In the days following abdominal surgery, patients' intestinal contents pass more slowly or not at all. New research at KU Leuven, Belgium, has now shown that this phenomenon - known as post-operative ileus or bowel paralysis - is not caused by the cells previously identified as the main players.
A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug-gefitinib (Iressa)-may be able to restore tamoxifen's anticancer activity.
› Verified 3 days ago